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Summary
The T cell product interleukin 5 (IL5) has been shown to be a key factor in the development
and the maturation of the eosinophilic cell lineage. We report here on the detection of human
IL5 receptors on eosinophilic sublines of the promyelocytic leukemia HL-60. Sodium butyrate,
which initiates differentiation to mature eosinophils, also induces the appearanceof high affinity
(Kd 1-5 x 10 -11 M) IL5 binding sites on these cells. The receptors are specific for 11,5, since
binding of radiolabeled ligand can only be inhibited with homologous or murine IL-5 and not
by other cytokines. We further show that the receptors are functional, since 116 can stimulate
the proliferation of these cells. Affinity crosslinking of surface-bound 1251 human IL-5 or 35S
mouse IL5 identified two membrane polypeptides of -60 and -130 kD to which 1175 is closely
associated. The presence of granuloryte/macrophage-colony-stimulating factor or tumor necrosis
factor during butyrate induction decreased the expression of 11,5 binding sites compared with
control cultures. The identification and characterization of human 1175 receptors on HL60 sublines
should provide new insight into the role of this cytokine in eosinophil differentiation.
E
osinophils are specialized granulocytes found in bloodand
peripheral tissues. They are present in relatively low
numbers in the circulation of healthy individuals, but their
number increases dramatically in certain pathological situa-
tions, such as parasitic infections and allergic diseases (reviewed
in reference 1). This selective eosinophilia suggests the exis-
tence ofa specific mechanism controlling eosinophilic growth
and/or differentiation. Although IL3, granuloryte/macro-
phage CSF (GM-CSF),' and IL5 all induce eosinophil differ-
entiation, only IL5 appears to be specific for the eosinophil
lineage. Both mouse (m) and human (h) 11,5 are potent and
specific stimuli for eosinophil colony formation in semisolid
cultures (2, 3), and for eosinophil growth and differentiation
in liquid cultures (4-6). Furthermore, IL-5 stimulates mouse
and human eosinophil function (7, 8). Also, there is evidence
pointing to the importance of IL5 as a mediator ofeosinophilia
in vivo. For example, antibodies against IL5 inhibit helminth-
induced eosinophilia in mice (9), and neutralize the activity
that converts normodense eosinophils to a functionally acti-
vated hypodense phenotype in serum of patients with idio-
pathic hypereosinophilic syndrome (10).
'Abbreviations used in this paper: Con A-sup, Con A supernatant; GM-
CSF, granuloryte/macrophage CSF; h, human; m, mouse; RT, room
temperature.
Murine IL5 was originally described as a T cell-replacing
factor (TRF) and as a B cell growth factor (BCGF II), based
on its capacity to induce proliferation and Ig secretion by
activated murine B cells (reviewed in reference 11). It has been
impossible to demonstrate similar activities of IL-5 on human
B cells in a wide range ofassay systems (12), apart from some
early conflicting reports (3, 13) . Nevertheless, hIL5 is active
on mouse B cells, but with very low specific activity. The
availability of IL5-responsive B cell leukemic cells and 11,5-
dependent early B cell lines facilitated the characterization
of IL5-Rs on murine B cells. 1175 binding sites displaying
both high (Kd 10-11 M) and low (10-9 M) affinity have been
found on a number of such cell lines (14, 15). Crosslinking
ofbound radiolabeled IL-5 gave evidence for two specifically
crosslinked polypeptides, suggesting that the IM associates
to more than one polypeptide chain at the cell membrane.
The complexity of the IL5R was further illustrated with the
isolation of several mAbs directed against epitopes on the IL
5R (16, 17) . Although all these antibodies inhibit IL5 bio-
logical activity and binding of IL-5 to mouse B cells, they
do not seem to recognize the same molecules. Some anti-
bodies immunoprecipitate predominantly polypeptides with
a molecular weight similar to that of the larger crosslinked
chain (16), while others recognize molecules that may cor-
respond to the smaller crosslinked polypeptide (17). Also, the
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antibodies do not overlap completely.
Much less is known about IIr5Rs on mouse or human
eosinophils . Oneexplanation for this is the lack of established
IL5-responsive eosinophilic cell lines. To our knowledge, no
such cell lines have been described so far. The humanpromye-
locytic leukemia cell lineHL60 has been an importantmodel
of myelocytic cellular differentiation (18) . By the addition
of specific chemical agents to theculturemedium, HIr60 can
be induced to mature to cells with many of the functional,
morphological, andbiochemical features ofmacrophages, neu-
trophils, or eosinophils (19, 20) . Under normal culturecon-
ditions, few HL60 cells differentiate to eosinophils (21, 22).
However, after passage in alkaline medium, HIr60 becomes
committed to differentiate primarily along the eosinophilic
lineage, when they are subsequently cultured in presence of
butyric acid (23) . We hypothesized that such cells, by analogy
with normal eosinophils, were capableof expressing I1r5Rs.
Here, we describe that HIr60, committed to eosinophil
differentiation, start to express specific high affinity binding
sites for 116 upon maturation induced by butyrate . We fur-
ther demonstrate that these receptors are functional and that
cell-bound 11,5 is associated with two membrane proteins
with molecular weights of "130,000 and "60,000.
Materials and Methods
Ce11Lines.
￿
HIr60 cells were obtained from theAmerican Type
Culture Collection (Rockville, MD)andwere maintained in RPMI
1640 medium (Gibco Laboratories, Grand Island,NY)supplemented
with 10% FCS(Gibco Laboratories) and gentamycin (25 Fog/ml) .
Clone 18.16 is asubdone ofHL-60 that was selected forIL5binding .
Briefly, cells were cloned at 100-300 cells/ml in RPMI 1640, 10%
FCS, 20 ng/ml human GM-CSF, and 0.92 methyl cellulose (24) .
After2wk, colonies were randomly picked andexpanded. Different
clones were then passaged in alkaline medium (pH 7 .6, 25 mM
Tricine) andinduced to differentiate with butyrate as described (20) .
One of the clones that showed specific binding of 11,5 (clone 18)
was subjected to a second round of subdoning . Clone 18.16 was
selected on the basis of highest 116 binding . Clone 15 and clone
2 cells are sublines of H1r60 with a tendency toward eosinophilic
differentiation . Their isolation and characterization have been de-
scribed elsewhere (25) . Aliquots of fresh cells were thawed every
month . To induce ILSRs, the cells were incubated at 2 x 105
cells/ml with 0.4 mM sodium butyrate for 7 d . B13 is an IL3-
or IL5-dependent Ly-1 * murine Pro-Blymphocyte clone (26), and
was kindly given to us byR. Palacios (Basel Institute for Immu-
nology, Basel, Switzerland) . These cells were cultured in DMEM
supplemented with 5% FCS, 25 ug/ml gentamycin, 50 ;&M 2-ME,
and 100 U/ml recombinant mIL5 .
CytokinesandmAbs.
￿
rhIL5was obtained from transformed Sac-
charompces cetmisiae and recombinant baculovirus-infected Sf9 cells,
as described elsewhere (27) . Baculovirus-derived 11,5 was purified
from the supernatant ofthe cells to homogeneity using single-step
immunoaffinity chromatography with an anti-hIL5mAb 5A5 U .
Van der Heyden, unpublished results, and see below). rmIIr5 was
also produced in the baculovirus system (27) and purified to
homogeneity. Briefly, the 50-80% (NH4)2SO4 precipitation frac-
tion of the Sf9 culture medium was dialyzed against 20mM Tris
HCl, pH 7.0, and loaded on a Mono-Q column (Pharmacia Fine
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Chemicals, Uppsala, Sweden) . Under these conditions, mIL5 does
not bind to the matrix, in contrast to the majority of proteins .
The flow trough wasbrought topH 9 .0 with ethanolamine and
reloaded on Mono-Q. The mIL5 that was bound to the matrix
this time was eluted at 65 mM NaCl usinga linear gradient . Pu-
rity (>95%) was evaluated by SDS-PAGE according to Laemmli
(28) . The biological activity of hIIr5 and mIL5 was 5 x 104 and
5 x 10' U/mg, respectively, as measured in the B13 proliferation
assay (see below) . 1 Uof IL5 is defined as the activity that causes
50% of themaximal incorporation. RecombinanthumanGM-CSF
andG-CSF were generous gifts ofDr. J. DeLamarter, and hIL10
was obtained fromDr.A. Shaw (both from Glaxo IMB, Geneva,
Switzerland) . rhI1r3 was kindly givenby Dr.Y Furuichi (Nippon
Roche Research Center, Kamakura, Japan) .Y Guisez (State Univer-
sity of Ghent) provided us with rhI1r6. Production and purification
of rhTNF-a have been described elsewhere (29) . Supernatant of
Con A-stimulated humanPBL (Con A-sup) was prepared by stan-
dard procedures . 5A5 is a mousemAb (IgG1 class) against hIIr5
that neutralizes biological activity, as measured in theB13 prolifer-
ation assay Q. VanderHeyden, unpublished results) . The rat anti-
IIx5R mAb R52.120 inhibits the biological activity ofmIL5 and
thebinding to its receptor (16), andwas kindly given to us by Dr.
A. Rolink (Basel Institute for Immunology). Human IgEwasob-
tained from Allergene, Dublin, Ireland .
Radiolabeling of IL5 .
￿
I'll-labeled hIL5 and mIL5 were pre-
paredfrom purified IL5 with theIODO-GEN (1,3,4,6-tetrachloro-
3a,6a-diphenylglycoluril) iodination reagent (Pierce Chemical Co .,
Rockford, IL) according to the manufacturer's instruction . Briefly,
40 jug of hIIr5 or mIL5 was incubated with 1 mCi Na '25I (sp
act, 2,000 Ci/mmol ; Amersham International, Amersham, UK)
in phosphate buffer, pH 7.6, for 10 min at 4°C in a glass tube
that was previously coated with 2 Wg iodogen . Radiolabeled 11,5
was separated on a gel filtration column (PD-10; Pharmacia Fine
Chemicals) in PBS containing0.25% gelatin.The specific radioac-
tivity of these preparations was routinely between3and10 p .Ci/wg
protein . After iodination, 10-50% of the IL5 remained biologi-
cally active, as determined in the B13 bio-assay (see below) . The
purity of the labeled hIIr5 was checkedby SDS-PAGE and autora-
diography (Fig. 1) . It consisted of a dimer with the expected mo-
lecular mass of 30kD. Biosynthetically labeled I'S mIL5 was pro-
ducedby injection inXenopus kevis oocytes ofSP6-RNApolymerase
transcripts made using a pSP64TmIL5 plasmid (27) . Batches of
five oocytes were incubated for3 d at 18°C in 50 pl oocyte medium
with 5,u1 "S-methionine (>1,000 Ci/mmol ; Amersham Interna-
tional) . Supernatants were collected and passed over a Sephadex-
G25 column to remove unincorporated "S-methionine . mIL5 was
found to be the major labeled protein upon SDS-PAGE analysis
(not shown) . The specific activity of the IIS-mIL5 was calculated
to be between 100 and 300 uCi/,ug.
BindingAssay.
￿
Binding was performed according to the pro-
tocol describedby Robb et al . (30) with minor modifications . 2.5
x 106 or 5 x 106 cells were incubated at 4°C or at room tem-
perature in 250wl binding medium (RPMI 1640 with 20% FCS)
with a constant amount of 12'I-hIL5, or with serial dilutions of
1251-labeled human or mouse 11,5 . To measure nonspecific binding,
a parallel series of tubes containing a 100-fold excess of cold IL5
wasincluded .To assess equilibrium binding of 11,5 to HL60 cells,
the samples were incubated for 2 h at 4°C . During incubation,
the tubes were placed on a rotation wheel to avoid aggregation
of the cells . Subsequently, the suspension was layered onto a 0.5-
ml phthalate oil (di-n-butylphthalate/dinonylphthalate, 2:1 [vol/vol],
density, 1.02 g/ml) mixture (31) in a 1.5-ml Eppendorf tube and
centrifuged at 12,000 rpm for 5 min . The tips of the tubes werecut off with a glowing razor blade, placed in vials, and counted
in a gamma counter (minigamma LKB ; LKB Instruments Inc .,
Turku, Finland) . Specific binding was determined as the difference
between total binding and nonspecific binding in the presence of
100-fold molar excess of cold ligand . The dissociation constant
(Kd) and number of binding sites per cell were calculated by
Scatchard analysis ofthe saturation binding data (32) with the com-
puter program LIGAND (33) . The number of binding sites was
calculated assuming that dimeric 11,5 bound to the receptor, since
the biologically active form of IL5 is a dimer (27, 34) .
IL5 Biological Assays.
￿
We measured the biological activity of
both mIL5 and hIL5 preparatesby testing their capacity to stimu-
late proliferation ofHL60 clone 15 and B13 cells . Butyrate-induced
HL60 done 15 cells grow independently ofexogenous added growth
factors, but proliferation can be increased twofold by addition of
11,5 orGM-CSF (see Results) . HL60 clone 15 cells were induced
to differentiate with 0.4mM sodium butyrate for 4 d before usage.
Murine B13 cells are completely dependent on IL3 or IL5 for growth
(26) . They were carefully washed and incubated in IL5-free medium
for 2 h to remove remaining traces ofIL5 . Cytokine samples were
serially diluted in 96-well fiat-bottomed microtiter plates (Nunc,
Roskilde, Denmark) in HL60 culture medium supplemented with
0.4 mM sodium butyrate or in B13 culture medium. 141,60 or B13
cells were plated at a density of 5 x 10'/ml in 200 Al medium .
Culture plates were incubated for 3 d at 37°C in a humidified at-
mosphere. Cell proliferation was determined by ['H]thymidine up-
take (0.5 gCi/well, 5 mCi/mmol; Amersham International) during
the last 6 h of the culture period. The data are expressed as the
mean counts per minute of triplicate cultures.
Chemical Crosslinking ofIL5 Binding Proteins on theHL60 Clone
15 Surface . 2 x 10' HL60 clone 15 cells were incubated for 2 h
at 4°C in 0.5 ml binding medium with 5 nM ' 251-hIL5 (10
ACi/Ag) or 1 nM 3'S-mIL5, alone or in presence of 100-fold
excess ofunlabeled ligand . Subsequently, the cells were washed twice
with ice-cold HBSS to remove unbound 11.6 . Crosslinking was
carried out with the homobifunctional crosslinker BY (bis [sul-
fosuccinimidyl] suberate; purchased from Pierce Chemical Co .) .
The reaction was performed essentially as described by Mita et al.
(14) . 107 cells were resuspended in 1 ml of HBSS, and crosslinker
(20 Al at 50 mM in dimethyl sulfoxide) was added to a final con-
centration of 1 mM. As control, the other half of the cells was
resuspended in HBSS with 20 Al dimethyl sulfoxide only. The
samples were incubated for 30 min on ice, and the reaction was
stopped by addition of 50 Al 1 M glycine during the last 5 min
of the incubation . Thereafter, cells were centrifuged, washed once
in 1 ml HBSS, and resuspended in 300 Al lysis buffer (PBS con-
Figure 1 . SDS-PAGE analysis
of labeled 6115. 1251-IL5 was
run under reducing (lane A) or
nonreducing (lane B) conditions
on a 12% acrylamide gel and
autoradiographed .
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Figure 2.
￿
Induction of IT-5 binding sites on HL-60 clones selected
for eosinophilic differentiation . Cells were incubated for the indicated
times in medium containing 0.4 mM Na-butyrate . 5 x 106 cells
were incubated with 0.8 nM 1251-hIL5 for 1 h at RT in presence or
absence of excess cold hIL5 . The number of 11,5 binding sites was
calculated after correction for nonspecific binding.
taining 2 mM EDTA, 2 mM EGTA, 2 mM PMSF, 10 AM pep-
statin, 10 AM leupeptin, 2mM o-phenantroline, 200 kallikrein in-
hibitor U/ml aprotinin, and 1% Triton X-100) . Nuclei and other
cell debris were removed by centrifugation for 10 min at 4°C in
a microcentrifuge . 150 Al of cell extract was analyzed on a 7.5%
SDS gel . After electrophoresis, the gel was exposed to X-OMAT
AR film (Kodak, Rochester, NY) . In case of crosslinking with 'sS-
mIL5, the gel was submerged in ENHANCE (New England
Nuclear, Boston, MA) before autoradiography .
Results
Induction ofIL5Binding Sites on Established Eosinophilic Sub-
linesfrom HL60. HL60 promyelocytic leukemia cells can
be induced to differentiate to neutrophils, macrophages, and
eosinophils. To select for cells expressing IL5Rs, HIr60 cells
were subcloned and cultured under conditions that allowed
differentiation along the eosinophilic cell lineage (see Materials
and Methods) . After differentiation, induced by butyrate, some
clones showed significant binding of 125I-hIL5 to their cell
surface (data not shown) . One of these, clone 18.16, displayed
-500 IL5 binding sites after 8d ofbutyrate treatment (Fig.
2) . Fischkoff isolated clones of HIr60, previously cultured
for prolonged periods under alkaline conditions, that differen-
tiated with a high rate to eosinophils, asjudged by morpho-
logical and cytochemical criteria (25) . The propensity of these
cells to differentiate to eosinophils persists for months after
they have been removed from the alkaline environment . Two
of these cell lines, clone 2 and clone 15, were induced to
differentiate with butyrate and were tested for IL -5 binding.
As can be seen in Fig. 2, both showed a gradual increase in
IL5 binding that reached maximal levels after 8 d ofexposure
to butyrate. Later time points showed no further increase (not
shown) . The number of IL5 binding sites on clone 2 was
comparable with that of clone 18.16 . In contrast, clone 15displayed three to four times more IL5 binding sites at its
cell surface. Noteworthy, this clone already showed IL-5
binding before maturation, but treatment with butyrate in-
creased the number of binding sites five- to sixfold . HL60
clone 15 was chosen for further analysis .
Specificity andKinetics ofRadiolabeled hIL5Binding to Butyrate
Induced HL60 Clone 15 Cells. To test the specificity of IL5
binding to HL60 cells, assays were performed in the pres-
ence of potential competitors for binding . Table 1 summa-
rizes the results of such analysis. Binding of labeled human
IL-5 can be successfully blocked with cold hIL5 and mIL5,
and with anti-hIL5 mAb 5A5, which is also a potent inhib-
itor ofhIL5 biological activity. hIL5 andmIL5 inhibit binding
at similar concentrations . Other cytokines, such as IL3, GM-
CSF, and IL6, fail to compete for 1251-IL5 binding . mAb
R52.120, which recognizes an epitope of the mIL5R and
Table 1 .
￿
Competition for the Binding of ' 2s1-labeled hIL-5 to
HL60 Clone 15 (Induced with 0.4 mM Na-butyrate for 7 d)
2 .5 x 106 cells and 3 x 10-1° M of 1251 IL-5 were incubated for
1 h at room temperature in 250 Al binding medium with indicated
amounts of cytokines or antibodies . The fraction of label bound to
the cells was determined as described in Materials and Methods .
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blocks binding ofmIL5 on mouse B cells (16), does not in-
terfere with IL5 binding on these human cells . To establish
optimal parameters for hIL5 binding to HL60, cells were
incubated at different temperatures for different times with
radiolabeled hIL5 . Measurement of the time course of 'zsl-
IL5 binding to these cells at 37°C showed a rapid associa-
tion of label . At 37°C and at room temperature (RT)
(±21°C), maximum levels of specific binding (after subtrac-
tion of nonspecific background) were reached after -10-15
min . Even at 4°C there was no significant change anymore
after 15 min . The total amount of cell-associated label at 37°C
started to decline after 30 min (Fig. 3) . At RT and at 37°C,
nonspecific binding kept increasing, while at 4°C, it remained
constant after -1 h . We therefore used incubation at 4°C
for further experiments.
Equilibrium Binding ofIL5 to HL60 Clone 15 Cells.
￿
Fig.
4 shows specific binding of 1251-hIL5 on butyrate-induced
HL60 clone 15 cells as a function of the concentration of
labeled IL5 . This experiment demonstrates that the binding
is saturable. Scatchard analysis of the data indicates the pres-
ence of a single class of binding sites . This particular experi-
ment gave estimates of 1,700 binding sites per cell and a Kd
of 22 pM. Table 2 is a summary of several binding experi-
ments performed with labeled hIL5 and/or mIL5 . From the
competition experiment (Table 1), we could expect that mIL5
would bind to HL60 with an affinity comparable with that
of hIL5 . Table 2 shows that this is indeed the case . In sepa-
rate binding experiments, we measured a Kd value between
10 and 50 pM for both hIL5 and mIL5 . mIL5-dependent
B cell lines display two classes (high and low affinity) of IL5Rs
(14, 15) . However, on HL60 cells, we found no evidence for
the existence of a second receptor with low affinity, even when
on Eosinophilic Cells
0
￿
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Figure 3 .
￿
Kinetics of binding of 1251-hIL5 to HL60 clone 15 cells
at different temperatures. Cells were induced for 7 d with butyrate,
as described in Materials and Methods . 2 .5 x 106 induced cells were
incubated with 2 nM 1251-hIL5 at indicated temperatures in presence
(filled symbols) or absence (open symbols) of 100-fold cold IL5 .
Exp . Inhibitor Dose 1251-hIL-5 bound
#g/ml
cpm
1 None 2,530
rhIL-5 0.17 473
1.70 82
17.00 29
rmIL-5 0.17 357
1.70 67
17.00 65
rhIL-3 0.13 2,461
1.30 2,519
13.00 2,554
rhGM-CSF 0.17 2,207
1.70 2,321
17.00 2,233
rhIL-6 0.17 2,396
1.70 2,344
17.00 2,690
2 None 1,522
rhIL-5 6.66 137
5A5 1 196
10 140
100 150
R52.120 0.8 1,396
8.4 1,470
84.0 1,440ligand concentration was increased to 30 nM (not shown) .
Treatment with butyrate increases the number of IIr5Rs but
does not alter significantly their affinity. The total number
of 11,5 binding sites varied considerably from one induction
to another. In the best case, we found -2,000 receptors per
cell . The reason for this variability is unclear. Perhaps subtle
differences in culture conditions during butyrate treatment
Summary of binding studies on HL-60 clone 15 . Cells (5 x 106)
were incubated at 4°C for 1.5-2 h in 250 Al binding medium . 1 to
4 are separate experiements. For each assay, between 6 and 12 differ-
ent doses of 12SI-IL-5 were used to calculate dissociation constant and
number of binding sites .
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Figure 4 .
￿
Saturation binding analysis of
human 1251-IL5 binding to butyrate-induced
HL60 clone 15 cells and (inset) Scatchard
transformation of the data. Cells (5 x 106)
were incubated for 2 h at 4°C in 250 Al
binding medium containing increasing
amounts of labeled 11,5 . The values were
corrected for nonspecific binding in presence
of 100-fold excess of unlabeled 11,5 .
such as cell density or pH of the medium influence the
efficiency of the induction .
Biological Activity ofIL5 onHL60 Clone 15 Cells .
￿
We in-
vestigated if the IL5Rs that we could detect on these cells
were functional, i.e., if they could transmit a biological signal .
Clone 15 cells are not dependent on IL5 for proliferation .
However, we found that IL5 increased their uptake of
[3H]thymidine by a factor of two (Table 3) . hIL5 and mIIL5
were equally efficient in stimulating this response. The con-
centration of IL5 that, on average, induced 50% of maximal
stimulation is in the range of 100 pg/ml or 3 x 10' 12 M,
i.e., -1/10 of theKd . GM-CSF also has a proliferative effect
on these cells, which is consistent with published data (35) .
While hIIL5 andmIL5 have comparable specific activities when
tested on HL60, we found, in agreement with others (12,
36), that the specific activity of hIL5 on murine B cells is
>100-fold lower than that of mIIr5 .
Affinity Crosslinking ofRadiolabeled IL5 toHL60 Cells.
￿
Nor-
mal H1r60 and clone 15 cells, cultured in presence or absence
of butyrate, were incubated with 1251_hIIr5 . Bound IL5 was
crosslinked with BS3, as described in Materials and Methods,
and the reaction products were analyzed by SDS-PAGE . The
results are shown in Fig . 5A . Two major IL5-crosslinked
complexes were identified in clone 15 cell extracts. In lysates
of cells induced to differentiate for 7 d with butyrate, the
same bands could be observed but their intensity was markedly
increased . The crosslinking products were specific for IL5
binding since excess of unlabeled IL5 or absence of cross-
linking reagent abolished the presence of the bands on the
gel . No bands could be detected in wild-type HIr60, sug-
gesting that their expression is correlated with the selection
for eosinophilic phenotype. The molecular mass of the ra-
Table 2 . Characterization ofIL-5 Rs on HL-60 Clone 15 Cells
IL-5 Rs
Binding sites
Exp . Induction 1251-IL-5 Kd(M-11 ) per cell
1 None Human 1.1 60
Butyrate (7 d) Human 3.2 300
2 Butyrate (7 d) Human 4.6 450
Butyrate (7 d) Mouse 1.2 210
3 Butyrate (7 d) Human 2.2 1,700
Butyrate (7 d) Mouse 5.0 1,150
4 Butyrate (7 d) Mouse 4.7 630diolabeled complexes was 145 and 75 kD. After substraction
of one IM monomer (the samples were loaded in presence
ofreducing agent), this corresponds to molecules of 130 and
60M Essentially similar results were obtained using 35S-
mIIL5 labeled to high specific activity in the oocyte system
(Fig . 5 B) . Two complexes of -175 and -95 kD could be
observed under nonreducing conditions from butyrate-induced
clone 15 cells. Under reducing conditions, an upper band of
150 kD and two lower bands of 82 and 75 kD could be
identified . The double band probably reflects heterogeneity
of the biosynthetically 35S-labeled IL5 due to differential
glycosylation (see uncrosslinkedIM molecules) . The forma-
tion of these radiolabeled complexes could be competed with
excess cold mIIr5 or hIIr5, indicating that both IL5 species
bind to the same molecules .
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Proliferation of butyrate-induced HL-60 clone 15 cells and of B13 cells was determined as described in Materials and Methods . The data
represent mean cpm ± SD . Values that correspond roughly to 50% of maximal growth stimulation are underlined .
Effect of Various Cytokines on ILSR Expression .
￿
Butyrate-
induced clone 15 cells expressed maatimally -2,000 ILSRs
per cell . We tried to increase this number by growing the
cells in the presence of different cytokines. Clone 15 cells were
incubated for 3 d in butyrate. Subsequently, various agents
were added during the last 4 d ofthe induction period . From
the different cultures, the same number ofcells were incubated
with 1251-11,5, and specifically bound IM was determined .
As can be seen in Fig. 6, none of the cytokines tested could
further increase IIr5R expression . In contrast, some factors
like TNF and GM-CSF, as well as supernatant from Con
A-stimulated lymphocytes, decreased IM binding. None of
the factors had a negative effect on the viability or the growth
rate of these cells (not shown) . IgE can activate eosinophils,
as monitored by the secretion of eosinophil peroxidase and
Figure 5.
￿
Chemical crosslinking
of IL5 binding proteins on H1r60
cells. (A) Wild-type HL60 cells
and clone 15 cells, cultured with
or without butyrate for 7 d, were
incubated with 1251-labeled hIL5 .
Membrane-bound labeled 11r5 was
crosslinked, as described in Ma-
terials and Methods, and the reac-
tion products were analyzed by
SDS-PAGE in presence of 2-ME.
The autoradiography was devel-
oped after 4 wk of exposure. The
uncrosslinked IL5 ran off the
7.5% gel . (B) Fluorograph of
crosslinking of 35S-labeled mIIr5
bound to butyrate-induced clone
15 cells. The crosslinked products
were analyzed under reducing and
nonreducing conditions. The auto-
radiography was exposed for 4 d.
Table 3. IL-5 Induced Proliferation of HL-60 Clone IS and B13 Cells
Agent added 10 2 10 1
Dose (ng/ml)
10 - ' 10-2 10-3
HL60 clone 15
hIL-5 44,118 ± 1,885 45,027 ± 1,394 43,603 ± 3,513 36,058 ± 1,305 24,499 ± 1,286 21,133 ± 949
mIL-5 42,852 ± 999 45,141 ± 631 42,556 ± 2,288 39,553 ± 440 25,794 ± 639 21,957 t 665
hGM-CSF 35,659 ± 210 42,295 ± 1,442 38,837 ± 433 35,140 ± 826 23,634 ± 1,122 22,385 ± 1,292
None 21,759 ± 1,024
B13
hIL-5 22,154 ± 2,318 8,553 ± 958 705 ± 129 55 ± 18 95 ± 44 75 ± 35
mIL-5 26,839 ± 717 25,713 ± 497 23,816 ± 419 9,937 ± 372 796 ± 30 146 ± 35
None 95 ± 36Figure 6.
￿
Effect of various reagents on IL5R expression . Clone 15
cells were cultured for 3 d in presence of butyrate. The suspension
was distributed at 2 .5 x 105 cells/ml into separate culture bottles in
medium with butyrate . Various agents were added at the following
concentrations : hTNF-a, 10; U/ml; h11,10, 1 ng/ml ; h1Ir6, 6 ng/ml ;
hIL3, 0.15 kg/ml; hGM-CSF, 10 ng/ml ; hG-CSF, 2 ng/ml ; h1gE,
1 ug/ml ; Con A-sup, 25% . The cells were further cultured for 4 d.
5 x 106 cells were incubated for 1 h at RT in 250 Ftl binding me-
dium containing 1 nM 1251-hlIr5 . The values were corrected for
nonspecific binding in presence of 100-fold excess of unlabeled 11,5 .
platelet-activating factor, and low affinity receptors for IgE
(Fc,R2, CD23) have been found on eosinophils (37, 38) .
But,we found no effect of IgE on IL-5R expression ofdone 15 .
Discussion
So far, the only well-established biological role of IL5 in
the human system is its activity as an eosinophil differentia-
tion factor. Consequently, we searched for suitable eosinophilic
cells to screen for hI1r5Rs. The promyelocytic leukemia cell
line H1r60 is capable of being selectively induced to differen-
tiate to eosinophils with butyric acid if they have previously
been cultured under alkaline conditions (23) . Here, we de-
scribe the detection and characterization ofIL5Rs on H1r60
sublines that were selected for their propensity towards eo-
sinophil differentiation . To our knowledge, this is the first
report on IL5R expression by human cells.
The production and function of eosinophils is controlled
by at least three hemopoietic growth factors, namely IL3,
GM-CSF, and IL5 . IL3 and GM-CSF bind to high affinity
receptors on the surface ofhuman eosinophils. The recipro-
cally inhibit each others binding, suggesting a common
binding protein (39) . The present study demonstrates that
binding of IM cannot be competed by IL3, GM-CSF, or
IIr6 . While IL3 and GM-CSF show potent stimulatory ac-
tivity for the proliferation ofhuman eosinophil precursors,
IM primarily supports the terminal maturation ofeosinophils
(40, 41) . The kinetics ofIL5R expression onHL60, asshown
in Fig. 2, coincides with the appearance of cells with a ma-
ture eosinophil phenotype (23), supporting the hypothesis
that IM acts at a later stage during eosinophilopoiesis .
Kinetic studies show that binding of radiolabeled hIL5
at 37°C is rapid and saturable. Scatchard analysis of equilib-
rium binding at 4°C provides evidence for a single class of
binding sites with a Kd of 1-5 x 10' 11M . The crosslinking
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experiments provide some structural information on IL5
binding molecules on HIr60 . Crosslinking with 1251-labeled
hIIr5 or biosynthetically 35S-labeled mIIr5 resulted in the de-
tection of two complexes of 145-150 and 75-85M The
increased mobility of the radiolabeled complexes under re-
ducing conditions is probably due to the loss of one of the
116 monomers present in the crosslinked ligand molecule.
If this is correct, our data indicate that the receptor is not
composed of disulphide-linked subunits . We further show
that IIr5 increases [3H]thymidine incorporation by clone 15
cells, which indicates that these I1r5Rs are functional . We
can observe important differences in the amount ofIL5 binding
sites from one butyrate induction to another (see Table 2) .
We do not know if this reflects a difference in numbers of
receptors per cell or whether the frequency of HL60 that
differentiate to MR-positive cells varies from one experi-
ment to another. However, ifwe assume that induced clone
15 cells display on average 1,000 binding sites/cell with a Kd
of30pM, ti 10%, or 100 receptor/cell, are occupied at a half-
maximal proliferative dose of IIr5 (3 x 10 -12 M) .
Binding of radiolabeled human j1r5 can be competed for
with cold hIL5 and mIL5 at similar concentrations (Table
1), and the number and affinity of binding sites for hIL5
and mIL5 are comparable (Table 2) . Both mIL5 and hIL5
inhibit the formation of 35S-mIL5-crosslinked complexes
(Fig . 5 B), which shows that they interact with the same
membrane components . Consistent with these findings, we
found that mIL5 has similar specific biological activity on
HIr60 proliferation as hIL5 (Table 3) . This is apparently in
contradiction with the results of Clutterbuck et al . (12), who
found that mIL5 is N20-fold less active on human bone
marrow than on homologous bone marrow. Since IM has
been shown to potentiate some eosinophil functions, such
as antibody-dependent cytotoxicity (42) and the production
of superoxide anion (7), it may well be that IL5, besides its
growth-stimulating activity, has other effects on H1r60 . In-
deed, it has been reported that IM can upregulate mRNA
levels for the granule contained proteins eosinophil cationic
protein and eosinophil-derived neurotoxin, in an eosinophilic
subline of HL60 (43) .
As mentioned before, on murine B cells, high and low
affinity IM binding sites can be detected. Experimental data
suggest that only the high affinity receptor can transmit a
biological signal (15) . Crosslinking of radiolabeled IL5 (14,
15, 17), and the characterization of cell surface molecules by
anti-IL5R mAbs (16, 17), revealed that at least two poly-
peptides (45-60M L chain ; and 130-140MH chain) com-
prise the IL5R. From their results, Mita et al. (15) concluded
that theH chain is associated with the high affinity IL5R .
Apparently, there is a good correlation between the amount
oflow affinity receptors on a particular cell line and the abun-
dance oftheL chain, as detected by affinity crosslinking. Based
on these data, two models for the I1r5R have been proposed :
(a) H andL chains correspond to high and low affinity binding
sites, respectively; and (b) IL5 binds with low affinity to the
L chain, and the high affinity receptor is composed of the
H and L chain, a situation comparable with the I1r2R (44) .
On HIr60, we can detect IL5 binding sites with a Kdsimilar to that of the high affinity IIr5R on murine B cells.
Affinity crosslinking indicates that membrane-bound IIr5 is
associatedwith two polypeptides with molecular masses com-
parable with H and L IIr5R chains on murine B cells. Induc-
tion of 116 binding on HIr60 correlates with a, concomitant
increase in intensity of the two crosslinked complexes (Fig.
5 A). Furthermore, butyrate treatment increases the number
of binding sites but does not alter significantly their affinity
(Table 2). Together, these observations suggest that both poly-
peptides form part of the high affinity receptor on human
eosinophils, which would be compatible with the second
model for the mouse receptor.
Assuming that the IIr5R on HIr60 is related-to that on
mouse B cells, we think of two possible explanations why
we only find high affinity receptors. Perhaps the L chain on
HIr60, in contrast to its counterpart on mouse B cells, cannot
bind 11,5 independently of the H chain. Alternatively, there
is an excess ofH chain at the cell surface, so that all thebinding
sites are converted to high affinity receptors. This hypothesis
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